Micafungin Bioglan (Micafungin)

Micafungin is an echinocandin antifungal indicated for several invasive Candida‑related conditions.

• Invasive candidiasis: effective treatment to eradicate bloodstream and deep‑tissue Candida infections.
• Candida esophagitis: resolves esophageal lesions and associated symptoms in immunocompromised patients.
• Febrile neutropenia: provides antifungal coverage when fever persists despite antibacterial therapy.
• Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection during the high‑risk post‑transplant period.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a critical structural component of the fungal cell wall. By blocking this pathway, the drug weakens the cell wall, leading to osmotic instability and fungal cell death, while having minimal effect on human cells that lack this polymer. The selective inhibition results in fungicidal activity against most Candida species and limited activity against Aspergillus.

Micafungin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Infusion‑related reactions: flushing, chills, or rigors during administration.
• Fever: transient elevated body temperature.
• Nausea: mild gastrointestinal discomfort.
• Headache: mild to moderate pain in the head.
• Elevated liver enzymes: transient increase in ALT/AST.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury requiring monitoring.
• Anaphylaxis: acute, potentially life‑threatening hypersensitivity.
• Stevens‑Johnson syndrome: severe skin and mucosal reactions.
• Severe neutropenia: marked reduction in neutrophil count.
• Renal impairment: acute kidney injury.
• Cardiac arrhythmia: irregular heart rhythm events.

When using Micafungin, clinicians should observe several safety precautions to minimize risk.

• Liver function monitoring: assess baseline enzymes and repeat during therapy.
• Renal function assessment: evaluate creatinine clearance before and during treatment.
• Hypersensitivity screening: discontinue if signs of anaphylaxis or severe rash appear.
• Concomitant hepatotoxic drugs: avoid or use with caution when combined with other liver‑affecting agents.
• Dose adjustment: consider reduced exposure in patients with severe hepatic impairment.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce micafungin exposure.
• Co‑administration with other hepatotoxic agents (e.g., azoles, high‑dose paracetamol): increased risk of liver injury.

Moderate Interactions (Monitor Closely)

• Calcineurin inhibitors (tacrolimus, cyclosporine) and mTOR inhibitors (sirolimus): may increase their plasma concentrations.
• Warfarin: potential alteration of INR; monitor coagulation parameters.
• Other antifungals (fluconazole, voriconazole): additive hepatic toxicity; observe liver function tests.